Cytek Biosciences, Inc.
CTKB
$3.65
-$0.02-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 277.86M | 277.78M | 277.21M | 270.09M | 262.41M |
| Total Receivables | 60.59M | 52.66M | 44.75M | 50.37M | 56.12M |
| Inventory | 44.01M | 46.86M | 50.12M | 54.93M | 61.17M |
| Prepaid Expenses | 4.64M | 3.15M | 2.80M | 4.61M | 3.99M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 9.35M | 9.76M | 9.20M | 8.66M | 8.37M |
| Total Current Assets | 396.45M | 390.19M | 384.08M | 388.65M | 392.06M |
|
|
|||||
| Total Current Assets | 396.45M | 390.19M | 384.08M | 388.65M | 392.06M |
| Net Property, Plant & Equipment | 28.13M | 28.63M | 27.44M | 28.20M | 29.26M |
| Long-term Investments | 16.66M | 16.18M | 16.18M | 16.18M | 16.18M |
| Goodwill | 16.66M | 16.18M | 16.18M | 16.18M | 16.18M |
| Total Other Intangibles | 20.13M | 20.49M | 21.42M | 22.25M | 23.08M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 36.53M | 34.13M | 34.60M | 35.19M | 33.87M |
| Total Assets | 499.50M | 491.23M | 483.73M | 492.07M | 494.46M |
|
|
|||||
| Total Accounts Payable | 5.53M | 5.39M | 3.19M | 3.73M | 3.03M |
| Total Accrued Expenses | 21.69M | 20.12M | 14.38M | 16.88M | 18.99M |
| Short-term Debt | 4.16M | -- | -- | 1.40M | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 4.26M | 5.53M | 4.33M | 2.82M | 3.01M |
| Total Finance Division Other Current Liabilities | 32.03M | 31.76M | 30.48M | 30.75M | 31.19M |
| Total Other Current Liabilities | 32.03M | 31.76M | 30.48M | 30.75M | 31.19M |
| Total Current Liabilities | 67.66M | 62.80M | 52.38M | 55.57M | 56.23M |
|
|
|||||
| Total Current Liabilities | 67.66M | 62.80M | 52.38M | 55.57M | 56.23M |
| Long-Term Debt | 1.05M | 1.24M | 1.33M | 1.48M | 1.65M |
| Short-term Debt | 4.16M | -- | -- | 1.40M | -- |
| Capital Leases | 7.55M | 7.76M | 8.11M | 8.70M | 9.48M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 27.50M | 33.97M | 32.78M | 33.71M | 34.04M |
| Total Liabilities | 103.76M | 105.76M | 94.60M | 99.45M | 101.39M |
|
|
|||||
| Common Stock & APIC | 430.92M | 430.20M | 435.10M | 429.52M | 423.52M |
| Retained Earnings | -35.20M | -44.84M | -45.78M | -35.35M | -29.18M |
| Treasury Stock & Other | 16.00K | 101.00K | -195.00K | -1.55M | -1.28M |
| Total Common Equity | 395.74M | 385.46M | 389.12M | 392.61M | 393.06M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 395.74M | 385.46M | 389.12M | 392.61M | 393.06M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 395.74M | 385.46M | 389.12M | 392.61M | 393.06M |
|
|
|||||